Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study
Open Access
- 19 November 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 17 (1) , 2418367
Abstract
Intravenous unfractionated heparin (IVUFH) and low molecular weight heparins (LMWH) are first line anticoagulants for the management of acutely unwell patients. The decision to prescribe either IVUFH or an LMWH is complex with minimal direction from clinical guidelines. The aim of this study was to explore individual prescribers' perceptions on prescribing IVUFH or LMWH in patients' acute management. Semi-structured interviews were conducted with purposively selected senior medical officers who were from specialities including cardiology, cardiothoracic surgery, respiratory, emergency, vascular surgery, nephrology, neurology and general medicine, identified as those that routinely prescribe IVUFH or LMWH. An interview tool with seven questions and four hypothetical case scenarios guided interview discussions. Interviews were audio recorded, transcribed and inductively coded for thematic analysis. Twelve doctors participated in interviews between February and October 2022. Mean interview duration was 24 min; data saturation was achieved. Most were senior doctors: one was a registrar and others were staff specialists. Three key themes emerged: (1) rationale for the choice of heparinoid, (2) patient safety considerations and (3) resources required. The themes and subthemes identified the complexity of issues to consider when choosing between IVUFH and LMWH. Multiple factors were considered by participants which were based on previous experiences and institutional capabilities rather than evidence-based medicine. Future interventions should focus on highlighting LMWH as the preferred heparinoid in most clinical scenarios. The use of IVUFH should be reserved for specific patient cohorts where the benefit of IVUFH outweighs the additional risks.Keywords
Funding Information
- Griffith University School of Pharmacy and Medical Science
- Gold Coast Hospital and Health Service Allied Health Research
This publication has 24 references indexed in Scilit:
- The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safetyExpert Opinion on Drug Safety, 2015
- The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosisNeurosciences, 2015
- Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patientsBlood Coagulation & Fibrinolysis, 2015
- Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary EmbolismArchives of internal medicine (1960), 2010
- Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical SettingsAnnals of Pharmacotherapy, 2009
- Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysisEuropean Heart Journal, 2007
- Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal InsufficiencyAnnals of Internal Medicine, 2006
- Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial InfarctionNew England Journal of Medicine, 2006
- Low molecular weight heparins versus unfractionated heparin for acute coronary syndromesCochrane Database of Systematic Reviews, 2003
- A Meta-analysis Comparing Low-Molecular-Weight Heparins With Unfractionated Heparin in the Treatment of Venous ThromboembolismArchives of internal medicine (1960), 2000